vs
博士伦（BLCO）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是罗致恒富的1.1倍（$1.4B vs $1.3B），博士伦同比增速更快（9.8% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs -6.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
BLCO vs RHI — 直观对比
营收规模更大
BLCO
是对方的1.1倍
$1.3B
营收增速更快
BLCO
高出15.6%
-5.8%
自由现金流更多
RHI
多$110.8M
$60.0M
两年增速更快
BLCO
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.3B |
| 净利润 | $-58.0M | — |
| 毛利率 | — | 37.6% |
| 营业利润率 | 8.0% | 1.7% |
| 净利率 | -4.1% | — |
| 营收同比 | 9.8% | -5.8% |
| 净利润同比 | -1833.3% | — |
| 每股收益（稀释后） | $-0.16 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORHI
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.5B | ||
| Q1 24 | $1.1B | $1.5B |
净利润BLCORHI
| Q4 25 | $-58.0M | — | ||
| Q3 25 | $-28.0M | $42.9M | ||
| Q2 25 | $-62.0M | $41.0M | ||
| Q1 25 | $-212.0M | $17.4M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $4.0M | $65.5M | ||
| Q2 24 | $-151.0M | $68.2M | ||
| Q1 24 | $-167.0M | $63.7M |
毛利率BLCORHI
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 37.2% | ||
| Q2 25 | — | 37.2% | ||
| Q1 25 | — | 36.9% | ||
| Q4 24 | — | 38.8% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 39.2% | ||
| Q1 24 | — | 38.1% |
营业利润率BLCORHI
| Q4 25 | 8.0% | 1.7% | ||
| Q3 25 | 7.4% | 1.0% | ||
| Q2 25 | -0.9% | 0.1% | ||
| Q1 25 | -7.3% | 2.9% | ||
| Q4 24 | 6.8% | 4.7% | ||
| Q3 24 | 3.6% | 4.1% | ||
| Q2 24 | 2.1% | 5.1% | ||
| Q1 24 | 0.5% | 2.8% |
净利率BLCORHI
| Q4 25 | -4.1% | — | ||
| Q3 25 | -2.2% | 3.2% | ||
| Q2 25 | -4.9% | 3.0% | ||
| Q1 25 | -18.6% | 1.3% | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | 0.3% | 4.5% | ||
| Q2 24 | -12.4% | 4.6% | ||
| Q1 24 | -15.2% | 4.3% |
每股收益（稀释后）BLCORHI
| Q4 25 | $-0.16 | $0.32 | ||
| Q3 25 | $-0.08 | $0.43 | ||
| Q2 25 | $-0.18 | $0.41 | ||
| Q1 25 | $-0.60 | $0.17 | ||
| Q4 24 | $-0.00 | $0.53 | ||
| Q3 24 | $0.01 | $0.64 | ||
| Q2 24 | $-0.43 | $0.66 | ||
| Q1 24 | $-0.48 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $464.4M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $1.3B |
| 总资产 | $14.0B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCORHI
| Q4 25 | $383.0M | $464.4M | ||
| Q3 25 | $310.0M | $365.3M | ||
| Q2 25 | $266.0M | $380.5M | ||
| Q1 25 | $202.0M | $342.5M | ||
| Q4 24 | $305.0M | $537.6M | ||
| Q3 24 | $329.0M | $570.5M | ||
| Q2 24 | $285.0M | $547.4M | ||
| Q1 24 | $315.0M | $540.9M |
总债务BLCORHI
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCORHI
| Q4 25 | $6.4B | $1.3B | ||
| Q3 25 | $6.4B | $1.3B | ||
| Q2 25 | $6.4B | $1.3B | ||
| Q1 25 | $6.4B | $1.3B | ||
| Q4 24 | $6.5B | $1.4B | ||
| Q3 24 | $6.6B | $1.5B | ||
| Q2 24 | $6.5B | $1.5B | ||
| Q1 24 | $6.7B | $1.5B |
总资产BLCORHI
| Q4 25 | $14.0B | $2.9B | ||
| Q3 25 | $13.8B | $2.8B | ||
| Q2 25 | $13.8B | $2.8B | ||
| Q1 25 | $13.4B | $2.7B | ||
| Q4 24 | $13.5B | $2.9B | ||
| Q3 24 | $13.5B | $3.0B | ||
| Q2 24 | $13.3B | $2.9B | ||
| Q1 24 | $13.3B | $2.9B |
负债/权益比BLCORHI
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $170.8M |
| 自由现金流率自由现金流/营收 | 4.3% | 13.1% |
| 资本支出强度资本支出/营收 | 5.4% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $266.8M |
8季度趋势，按日历期对齐
经营现金流BLCORHI
| Q4 25 | $136.0M | $182.5M | ||
| Q3 25 | $137.0M | $77.4M | ||
| Q2 25 | $35.0M | $119.4M | ||
| Q1 25 | $-25.0M | $-59.3M | ||
| Q4 24 | $22.0M | $154.8M | ||
| Q3 24 | $154.0M | $129.6M | ||
| Q2 24 | $15.0M | $142.0M | ||
| Q1 24 | $41.0M | $-15.9M |
自由现金流BLCORHI
| Q4 25 | $60.0M | $170.8M | ||
| Q3 25 | $63.0M | $63.6M | ||
| Q2 25 | $-54.0M | $104.2M | ||
| Q1 25 | $-135.0M | $-71.7M | ||
| Q4 24 | $-70.0M | $140.5M | ||
| Q3 24 | $94.0M | $111.8M | ||
| Q2 24 | $-57.0M | $129.6M | ||
| Q1 24 | $-26.0M | $-27.7M |
自由现金流率BLCORHI
| Q4 25 | 4.3% | 13.1% | ||
| Q3 25 | 4.9% | 4.7% | ||
| Q2 25 | -4.2% | 7.6% | ||
| Q1 25 | -11.9% | -5.3% | ||
| Q4 24 | -5.5% | 10.2% | ||
| Q3 24 | 7.9% | 7.6% | ||
| Q2 24 | -4.7% | 8.8% | ||
| Q1 24 | -2.4% | -1.9% |
资本支出强度BLCORHI
| Q4 25 | 5.4% | 0.9% | ||
| Q3 25 | 5.8% | 1.0% | ||
| Q2 25 | 7.0% | 1.1% | ||
| Q1 25 | 9.7% | 0.9% | ||
| Q4 24 | 7.2% | 1.0% | ||
| Q3 24 | 5.0% | 1.2% | ||
| Q2 24 | 5.9% | 0.8% | ||
| Q1 24 | 6.1% | 0.8% |
现金转化率BLCORHI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | 1.98× | ||
| Q2 24 | — | 2.08× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
